72
Participants
Start Date
June 1, 2015
Primary Completion Date
August 14, 2015
Study Completion Date
August 14, 2015
Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide FDC
A tablet containing DRV 800 mg, COBI 150 mg, FTC 200 mg and TAF 10 mg as FDC will be administered.
Elvitegravir /Cobicistat/Emtricitabine/Tenofovir alafenamide FDC
A tablet containing EVG 150 mg, COBI 150 mg, FTC 200 mg and TAF 10 mg as FDC will be administered.
Darunavir
A tablet containing Darunavir (DRV) 800 mg will be administered.
Emtricitabine/Tenofovir alafenamide (FTC/TAF)
A tablet containing Emtricitabine (FTC) 200 mg and Tenofovir alafenamide (TAF) 10 mg will be administered.
Cobicistat
A tablet containing cobicistat (COBI) 150 mg will be administered.
High-fat Breakfast
High-fat breakfast will be administered.
Standardized Regular Breakfast
Standardized regular breakfast will administered.
Antwerp
Janssen Sciences Ireland UC
INDUSTRY